Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
Study sponsor: BioLineRx, Ltd. · BLRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-09-06Actual
Enrollment · participants80Actual
Source updated2024-08-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.